NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 560 participants.

Also called NCT02305485

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 560 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02305485
Other papers using this trial's data
  • 5-Year Outcomes With a Novel Coronary Sirolimus-Eluting Bioresorbable Scaffold: The NeoVas Randomized Trial JACC. Cardiovascular interventions, 2025-09-08 DOI, PubMed 40930600
  • A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents JACC. Cardiovascular interventions, 2018-02-12 DOI, PubMed 29413240

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02305485. Randomized; single masking; primary purpose treatment. Start 2014-11 (registry gives no type); primary completion 2016-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial
Intervention (Device)
NeoVas BCS
Intervention (Device)
XIENCE PRIME EECSS
Lead sponsor
Lepu Medical Technology (Beijing) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02305485
Content hash
50e9ec61af2671760ae0c7fa41f9625453d95d4f732cfa898a2be2919a1045b2